The identification of the molecular mechanisms underlying the pathogenesis of APDS has facilitated “personalised” treatment options, such as PI3Kδ inhibition rather than reliance on generic therapies, but even more personalisation of treatment, guided by assessment of degrees of PI3K pathway regulation, is likely to improve outcomes further. This evidence concerns the gene PIK3CD and activated PI3K-delta syndrome.